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Introduction: Few data are available in regards to the prevalence of pulmonary hypertension 
(PH) in the broad spectrum of COPD. This study was aimed at assessing the prevalence of 
PH in a cohort of COPD patients across the severity of airflow limitation, and reporting the 
hemodynamic characteristics at rest and during exercise.
Methods: We performed a retrospective analysis on COPD patients who underwent right-heart 
catheterization in our center with measurements obtained at rest (n=139) and during exercise 
(n=85). PH was defined as mean pulmonary artery pressure (mPAP) $25 mmHg and pulmonary 
capillary wedge pressure ,15 mmHg. Exercise-induced PH (EIPH) was defined by a ratio of 
ΔmPAP/Δcardiac output .3.
Results: PH was present in 25 patients (18%). According to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) classification, PH prevalence in GOLD 2 was 7% (3 patients); 
25% (14 patients) in GOLD 3; and 22% (8 patients) in GOLD 4. Severe PH (mPAP $35 mmHg) 
was identified in four patients (2.8%). Arterial partial oxygen pressure was the outcome most 
strongly associated with PH (r=-0.29, P,0.001). EIPH was observed in 60 patients (71%) 
and had a similar prevalence in both GOLD 2 and 3, and was present in all GOLD 4 patients. 
Patients with PH had lower cardiac index during exercise than patients without PH (5.0±1.2 
versus 6.7±1.4 L/min/m2, respectively; P=0.001).
Conclusion: PH has a similar prevalence in COPD patients with severe and very-severe airflow 
limitation, being associated with the presence of arterial hypoxemia. In contrast, EIPH is highly 
prevalent, even in moderate COPD, and might contribute to limiting exercise tolerance.
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Introduction
Pulmonary hypertension (PH) is a relevant complication in the natural history of 
patients with chronic obstructive pulmonary disease (COPD), since its presence is 
associated with shorter survival, increased risk of exacerbations, and greater use of 
health care resources.1 The actual prevalence of PH in COPD remains unsettled and 
varies widely according to the targeted population, the definition applied, and the 
diagnostic approach used to identify PH.2 Right-heart catheterization is the gold 
standard to diagnose PH.3 In COPD, most hemodynamic studies have been performed 
in patients with advanced disease in whom PH is expected to occur more frequently, 
with a prevalence of PH ranging from 23%–91%.4–12 Information on the prevalence 
of PH in patients with milder disease is scarce. Based on the former Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) spirometric classification,13 Hilde 
et al14 reported a prevalence of 5%, 27%, and 53% in patients with GOLD stages 2, 3, 
and 4, respectively.
Patients with COPD may develop PH during exercise, a condition associated with 
an increased risk for subsequently developing PH at rest.12 Current understanding of 
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the hemodynamic response of the pulmonary circulation to 
exercise in patients with COPD and its impact over exercise 
intolerance is limited. Studies have shown a cardiovascular 
limitation to exercise in patients with severe PH which 
seems to be distinct from the ventilatory exhaustion usually 
observed in COPD.15,16
In order to expand our understanding of the hemo-
dynamic profile of PH across the spirometric degrees 
of COPD, we analyzed data from 139 COPD patients 
assessed by right-heart catheterization at rest. A subset 
of these patients (n=85) had hemodynamic measurements 
during exercise. The main objective of the present study 
was to assess the prevalence of PH in this cohort of patients 
according to the GOLD spirometric grades. Secondary aims 
were to describe the hemodynamic characteristics at rest 
and during exercise, and to analyze the potential relation-
ships between pulmonary hemodynamics and lung function 
tests.
Methods
This was a retrospective study, which included data from 
seven previously reported studies.17–23 All studies were 
approved by our institutional ethics committee and the pro-
cedures were performed after obtaining written informed 
consent. All involved patients were clinically stable (ie, at 
least 3 months from the last COPD exacerbation), without 
cardiac failure or other coexisting chronic respiratory dis-
ease, and received regular treatment for COPD, including 
long-term oxygen if it was deemed necessary. No patient 
was treated with PH targeted therapy, namely prostanoids, 
endothelin-receptor antagonists, or phosphodiesterase-5 
inhibitors. All were current (n=53) or former (n=86) smokers 
($10 pack-year). Patients were classified according to the 
GOLD spirometric grade system.24
PH was defined by a mean pulmonary artery pressure 
(mPAP) $25 mmHg and a pulmonary capillary wedge pres-
sure (PCWP) ,15 mmHg.2 Severe PH was considered when 
mPAP was $35 mmHg or $25 mmHg along with a cardiac 
index (CI) ,2.0 L/min/m2, according to the most updated 
clinical classification of PH in chronic lung diseases.3 An 
abnormal increase of mPAP during exercise was considered 
when the change in mPAP ([ΔmPAP] in mmHg) was .3- 
times greater than the change in cardiac output ([CO] in 
L/min) (ΔCO).14,25 As age may influence exercise mPAP, we 
also analyzed the mPAP values during exercise according to 
those reported by Kovacs et al26 who established the upper 
limit of normal as 30 mmHg for subjects ,50 years and as 
46 mmHg for subjects $50 years.
Measurements
lung function
Forced spirometry, static lung volumes, and single-breath 
carbon monoxide diffusing capacity (DLco) were measured 
according to the American Thoracic Society/European Respi-
ratory Society recommendations,27 using our own predicted 
equations.28–29 Arterial blood gas samples were drawn for 
measuring partial pressure of arterial oxygen (PaO
2
), partial 
pressure of arterial carbon dioxide (PaCO
2
), and pH at rest 
and during exercise.
right-heart catheterization
A triple-lumen Swan–Ganz catheter (Edwards Laboratories, 
Santa Ana, CA, USA) was placed into the pulmonary artery 
under pressure wave monitoring (M1166A; Hewlett-Packard, 
Boeblingen, Germany). Transducers were zeroed at the level 
of right atrium. Right atrial pressure (RAP), pulmonary 
artery pressure (PAP), and PCWP were measured at the 
end of expiration. CO was measured by thermodilution and 
expressed as the mean of three measurements. CI, pulmonary 
vascular resistance (PVR), and total pulmonary resistance 
were calculated using standard formulae.30
exercise measurements
Prior to catheterization, the highest workload that patients 
could tolerate was determined by an incremental exercise 
test on a cycle ergometer in 85 subjects. The workload was 
increased using a ramp of 5 Watts every minute until the 
maximal load limited by symptoms was achieved. Hemo-
dynamic and gas exchange measurements were performed 
in the semirecumbent position at a workload equivalent 
to 60% of the maximal workload tolerated in the previous 
incremental test.
statistical analysis
Data are expressed as mean ± standard deviation unless oth-
erwise stated. One-way analysis of variance with Bonferroni 
correction was used to compare more than two groups. Rela-
tionships between variables were assessed using Pearson’s 
or Spearman’s correlation coefficients depending on data 
distribution. Changes in hemodynamic data from rest to 
exercise were compared using paired t-tests. The Mann–
Whitney U-test was used to assess CI during exercise in 
patients with and without PH. Estimations of risk for PH were 
made using odds ratios and their 95% confidence intervals 
from univariate logistic regression models for PaO
2
, DLco, 
PaCO
2
, inspiratory capacity, or forced expiratory volume in 
1 second (FEV
1
). In order to assess a multivariate model, we 
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used a forward stepwise procedure with a criterion of 0.05 to 
select variables for the final model. All data were analyzed 
with SPSS version 18 and P-values ,0.05 were considerate 
as statistically significant.
Results
The means (± standard deviation) of demographic and lung 
function measurements for all participants are given in Table 
1 as a function of the current GOLD spirometric classifi-
cation.24 One hundred and thirty-nine patients (134 men, 5 
women) were included. Mean age was 63±8 years. The mean 
of post-bronchodilator FEV
1
 was 41%±16% of predicted; 
PaO
2
 was 69±12 mmHg; PaCO
2
 was 40±6; and alveolar–
arterial oxygen partial pressure difference (AaPO
2
) was 
32±10 mmHg. Thirty-seven patients were under long-term 
oxygen therapy.
hemodynamic characteristics at rest
Table 2 shows the hemodynamic measurements at rest. The 
mean mPAP of the whole cohort was 20±8 mmHg. PH was 
present in 25 patients (18% of cases of the whole cohort). 
Most of them had severe or very-severe airflow limitation, 
although PH prevalence was similar in GOLD 3 and 4.
Mean PVR was normal in GOLD 2 and 3, although with a 
wide dispersion, and elevated in GOLD 4. RAP, PCWP, and 
CI were on average within normal range in all GOLD grades. 
The CI correlated with FEV
1 
(r=0.38, P,0.001). Severe PH 
was noticed in four patients (2.8% of the whole cohort). All 
of them were male. Their lung function and hemodynamic 
characteristics are listed in Table 3.
hemodynamic characteristics during 
exercise and changes in blood gases
Both mPAP and PCWP increased significantly during exer-
cise in all GOLD grades (Figure 1; Table 4). An abnormal 
increase of mPAP during exercise, defined by a ΔmPAP/ΔCO 
ratio .3, was observed in 60 patients (71%): 28 patients 
(70%) were in GOLD 2, 26 (67%) in GOLD 3, and the 
remaining six patients in GOLD 4. During exercise, patients 
with PH, compared with those without PH, had lower CI 
(5.0±1.2 and 6.7±1.4 L/min/m2, respectively; P=0.001) 
(Figure 2). Patients with associated PH had, as compared 
with patients without PH, lower PaO
2
 and higher PaCO
2
 both 
at rest and during exercise (Table 5).
Variables associated with Ph
In the univariate analysis, the following outcomes were 
associated with the presence of PH at rest: PaO
2
;
 
DLco
 
(% predicted); PaCO
2
; inspiratory capacity (% predicted); 
and FEV
1
 (% predicted). In the stepwise multiple regression 
Table 1 anthropometric and functional characteristics of 139 patients grouped according to gOlD spirometric grades
All GOLD grade ANOVA
P-value2 3 4
n 139 46 56 37
sex, M/F 134/5 46/0 53/3 35/2
age (yr) 63±8 63±8 63±7 60±7 ns
BMI (m/kg2) 25±4 24±4 26±3 24±4 ns
FVC (% pred) 72±18 82±14 71±17* 60±17*,≠ ,0.001
FeV1 (l) 1.3±0.6 1.9±0.5 1.2±0.2* 0.7±0.2*,≠ ,0.001
FeV1 (% pred) 41±16 59±7 39±6* 20±4*,≠ ,0.001
FeV1/FVC (%) 40±15 52±8 41±14* 25±8*,≠ ,0.001
TlC (% pred) 116±21 113±17 112±22 124±22≠ 0.004
rV (% pred) 200±75 156±44 191±69* 266±68*,≠ ,0.001
IC (% pred) 62±18 76±16 63±16* 47±12*,≠ ,0.001
rV/TlC (%) 61±11 52±8 59±9* 71±8*,≠ ,0.001
IC/TlC ratio 0.26±0.07 0.32±0.06 0.27±0.07* 0.18±0.05*,≠ ,0.001
Dlco (% pred) 57±25 72±23 59±21* 36±15*,≠ ,0.001
PaO2 (mmhg) 69±12 77±10 68±11* 62±11*,≠ ,0.001
PaCO2 (mmhg) 40±6 37±4 41±6* 45±7*,≠ ,0.001
aaPO2 (mmhg) 32±10 30±11 32±9 34±10 ns
Notes: Data are presented as means ± standard deviation. Significant differences within each variable are indicated as: *different from GOLD grade 2; ≠different from gOlD 
grade 3.
Abbreviations: aaPO2, alveolar–arterial oxygen partial pressure difference; anOVa, analysis of variance; BMI, body mass index; Dlco, diffusing capacity for carbon dioxide; 
FeV1, post-bronchodilator forced expiratory volume in 1 second; FeV1/FVC, post-bronchodilator forced expiratory volume in 1 second/post-bronchodilator forced vital 
capacity; FVC, post-bronchodilator forced vital capacity; gOlD, global Initiative for Chronic Obstructive Pulmonary Disease; IC, inspiratory capacity; IC/TlC, inspiratory 
capacity/total lung capacity ratio; M/F, male/female; NS, not significant; PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen; pred, 
predicted; rV, residual volume; rV/TlC, residual volume/total lung capacity ratio; TlC, total lung capacity.
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model, PaO
2 
was the only covariate associated with the pres-
ence of PH (Table 6).
Discussion
The current study, which includes pulmonary hemody-
namic measurements at rest and during exercise in a stable 
population of COPD across the whole spirometric spectrum 
of severity, identified several findings. First, the overall 
prevalence of PH in our cohort was relatively low (18%). 
Second, patients in GOLD 3 and 4 had similar a prevalence 
of PH. Third, a significant increase of both mPAP and PCWP 
during exercise was noticed in all patients with a high pro-
portion of an “exercise hypertensive response” in the entire 
cohort. And fourth, CI during exercise was affected by the 
presence of PH.
Data about the prevalence of PH in COPD, particularly 
in patients with moderate-to-severe COPD, is limited. The 
prevalence found in our study was lower than in a recent 
study by Hilde et al14 who reported a prevalence of PH of 
27% in stable patients in GOLD 2–4. Interestingly, the preva-
lence of PH observed in the present study in patients with 
GOLD 2 and 3 was similar to that reported by Hilde et al.14 
In contrast, the prevalence of PH in patients with GOLD 4 
was lower in our study (22%) than in Hilde’s study (53%). 
This discrepancy may be due to the fact that the current 
GOLD spirometric classification, which we used, does not 
consider arterial blood gas measurements for the definition 
of GOLD 4.24 Accordingly, in patients with severe-to-very-
severe COPD, the degree of airflow limitation is not related 
to the presence of PH. What makes a difference regarding 
PH in those patients is the presence of concomitant abnormal 
pulmonary gas exchange. In fact, if we classify patients in 
our series according to the previous GOLD classification, the 
prevalence of PH in GOLD 4 stage is 33%, in line with that 
reported by Hilde et al.14 That said, we cannot overlook that 
the current A-B-C-D GOLD classification, based on a mul-
tidimensional assessment of airflow limitation, symptoms, 
and risk of exacerbations,24 might more accurately identify 
differences in PH prevalence between categories. Neverthe-
less, the retrospective nature of our study precludes such a 
combined assessment.
As previously reported, the degree of PH in this cohort 
was of mild-to-moderate magnitude with a well preserved 
CO, and mPAP correlated with airflow obstruction 
Table 2 Pulmonary hemodynamics at rest of 139 patients grouped according to the gOlD spirometric grades
All GOLD grade ANOVA
P-value2 3 4
n 139 46 56 37
mPaP (mmhg) 20±8 18±6 21±9 21±6 ns
PCWP (mmhg) 6±4 7±4 6±4 5±3 ns
raP (mmhg) 2.9±3.2 3.4±3.5 2.1±3.2 2.7±2.7 ns
CO (l/min/m2) 5.6±1.4 6.3±1.5 5.5±1.3* 4.7±0.8*,≠ ,0.001
CI (l/min/m2) 3.2±0.8 3.6±0.8 3.1±0.7* 2.8±0.6*,≠ ,0.001
TPr (dyn⋅s⋅cm-5) 306±158 244±105 322±197* 355±191*,≠ 0.004
PVr (dyn⋅s⋅cm-5) 218±143 160±88 233±185* 264±97*,≠ 0.003
TPg 14±7 12±5 15±8 16±5*,≠ 0.02
Patients with Ph, n (%) 25 (18) 3 (7) 14 (25) 8 (22)
Notes: Data are presented as mean ± standard deviation. Significant differences within each variable are indicated as: *different from GOLD grade 2; ≠different from gOlD 
grade 3.
Abbreviations: anOVa, analysis of variance; CI, cardiac index; CO, cardiac output; gOlD, global Initiative for Chronic Obstructive Pulmonary Disease; mPaP, mean 
pulmonary artery pressure; NS, not significant; PCWP, pulmonary capillary wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right 
atrial pressure; TPg, transpulmonary pressure gradient; TPr, total pulmonary resistance. 
Table 3 subject characteristics in four COPD patients with severe pulmonary hypertension
Age 
(years)
FEV1  
(% pred)
DLco  
(% pred)
PaO2  
(mmHg)
PaCO2  
(mmHg)
mPAP  
(mmHg)
PCWP  
(mmHg)
PVR 
(dyn⋅s⋅cm-5)
CI  
(L/min/m2)
58 35 34 44 46 35 4 594 2.75
65 51 24 50 35 43 6 566 2.69
58 46 22 50 38 38 2 1,080 1.79
61 39 21 46 44 61 11 941 2.38
Abbreviations: COPD, chronic obstructive pulmonary disease; CI, cardiac index; Dlco, diffusing capacity for carbon dioxide; FeV1, post-bronchodilator forced expiratory 
volume in 1 second; mPAP, mean pulmonary artery pressure; NS, not significant; PaO2, partial pressure of arterial oxygen; PaCO2, partial pressure of arterial carbon dioxide; 
PCWP, pulmonary capillary wedge pressure; pred, predicted; PVr, pulmonary vascular resistance.
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Figure 1 Changes from rest to peak exercise in the hemodynamic variables in 85 patients who underwent exercise testing, grouped according gOlD stage.
Note: P-value differences from rest to exercise (paired t-tests).
Abbreviations: CI, cardiac index; gOlD, global Initiative for Chronic Obstructive Pulmonary Disease; mPaP, mean pulmonary artery pressure; PCWP, pulmonary capillary 
wedge pressure; PVR, pulmonary vascular resistance; NS, not significant.
Table 4 Pulmonary hemodynamics during submaximal exercise in patients grouped to the gOlD spirometric grades (n=85)
All GOLD grade ANOVA
P-value2 3 4
hemodynamics during exercise, n 85 40 39 6
mPaP (mmhg) 42±14 38±11 45±15 52±7 0.019
PCWP (mmhg) 20±9 19±9 21±10 20±6 ns
CO (l/min/m2) 11.8±2.8 12.2±2.8 11.7±2.8 9.5±2.2 ns
CI (l/min/m2) 6.5±1.5 6.7±1.5 6.3±1.5 5.4±1.1 ns
TPr (dyn⋅s⋅cm-5) 315±174 265±105 345±215 454±146* 0.014
PVr (dyn⋅s⋅cm-5) 171±134 136±72 191±173 274±86 0.02
TPg (mmhg) 22±11 19±8 24±13 31±7* 0.02
ΔmPaP/ΔCO (mmhg/l/min) 4.8±3.7 4.1±2.2 5.4±4.8 6.4±2.7
abnormal mPaPa, n (%) 29 (34) 8 (20) 17 (46) 4 (67)
ΔmPaP/ΔCO .3, n (%) 60 (71) 28 (70) 26 (67) 6 (100)
Notes: Data are presented as mean ± standard deviation. amPaP: ,50 years, .30 mmhg; $50 years, .46 mmhg. according to Kovacs et al.26 Significant differences within 
each variable are indicated as: *different from gOlD grade 2.
Abbreviations: gOlD, global Initiative for Chronic Obstructive Pulmonary Disease; Δ, change; anOVa, analysis of variance; CI, cardiac index; CO, cardiac output; 
mPAP, mean pulmonary artery pressure; NS, not significant; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; TPG, transpulmonary pressure 
gradient; TPr, total pulmonary resistance.
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severity.1,31 In the whole cohort, both resting PCWP and 
RAP were within normal limits. The prevalence of patients 
with severe PH (2.8%) in our study is comparable with 
other reported series.6,7,9 Likewise, patients with severe PH 
showed less severe airflow limitation, more severe arterial 
hypoxemia, and lower DLco than patients with moderate 
PH. It is important to identify these patients with predomi-
nant vascular involvement since they represent a clinically 
distinct phenotype within the COPD population that carries 
poor prognosis.6,9,32
The exercise-induced increase in mPAP was interpreted 
according to the increase in CO as proposed by recent 
reports.14,25 The latter proposal is based on the concept that 
during exercise, the pulmonary microcirculation is progres-
sively recruited under physiological conditions, resulting in 
the maintenance of relatively low arterial pressure despite 
increasing flow.33 The abnormal increase in mPAP during 
exercise in COPD patients has been documented in differ-
ent studies.12,14,16,34 In spite of the fact that there is no current 
definition of exercise-induced PH, we observed that 71% of 
the patients developed a “hypertensive response”, defined 
on the basis of pressure/flow relationships. Such an abnor-
mal vascular response was noticed even in moderate grades 
of COPD severity, whereas it was present in all GOLD 4 
patients. The clinical significance of the increased PAP 
during exercise remains to be established. Conceivably, it 
could limit exercise capacity. In fact, an increased mPAP 
has been associated with poor results in the 6 minutes 
walking test.5,10 Furthermore, a PAP threshold .30 mmHg 
during exercise is a strong predictor for the development 
of PH in the long-term.12 We also found that PVR does 
not decrease during exercise in GOLD grades 3 and 4, in 
contrast with what occurs in healthy subjects.35 This fall 
in PVR during exercise is explained by the distensibility 
of resistive pulmonary vessels. Reduced pulmonary artery 
compliance observed in COPD might explain this response.14 
Furthermore, CI during exercise was lower in patients with 
associated PH. Although ventilatory impairment is the main 
factor limiting exercise tolerance in COPD, it cannot be dis-
regarded that hemodynamic alterations may also contribute 
to exercise intolerance. Indeed, Boerrigter et al15 reported a 
distinctive exercise pattern in COPD patients with severe 
PH (mPAP .40 mmHg). Although in our study the limited 
number of patients with severe PH precluded an analysis in 
this subset of patients, the finding of lower CI values during 
exercise in patients with PH concurs with the findings by 
Boerrigter et al.15
Pulmonary gas exchange impairment was associated 
with the presence of PH. However, the fact that patients 
without arterial hypoxemia also had PH in our cohort 
underlines the concept that the genesis of PH is complex 
and multifactorial.36 The weak correlation in COPD between 
PH and lung function measurements has been largely known 
and fits with our results.7,11,34 This makes it difficult in daily 
clinical practice to use predictive models to identify patients 
with pretest probability of presenting PH. Skjørten et al37 
suggested that PaO
2
 values at rest and peak exercise below 
71 mmHg and 64 mmHg, respectively, indicate the need for 
further evaluation of coexisting PH. In our study, we failed to 
find an adequate model with functional variables that could 
help to predict the presence of PH.
Our investigation has some limitations. First, there is 
the possibility that selection bias might have influenced the 
significance of our findings due to its retrospective, single-
center, and observational design. However, because the 
purpose of the study was to describe PH and hemodynamic 
characteristics in COPD patients with different grades of 
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Figure 2 Cardiac index during exercise in patients with and without pulmonary 
hypertension (n=85).
Note: P-value indicates comparison between Ph and non-Ph (Mann–Whitney 
U-test).
Abbreviations: CI, cardiac index; Ph, pulmonary hypertension.
Table 5 Arterial blood gas profile at rest and during exercise in 
85 patients with or without pulmonary hypertension
No PH  
(n=73)
PH  
(n=12)
P-value
PaO2 (mmhg) 76±8 65±14 0.020
PaO2 exercise (mmhg) 74±12 54±11 0.001
PaCO2 (mmhg) 38±4 44±6 0.006
PaCO2 exercise (mmhg) 41±8 47±6 0.004
Note: Data are presented as mean ± standard deviation.
Abbreviations: PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial 
pressure of arterial oxygen; Ph, pulmonary hypertension.
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airflow limitation, we believe that the population addresses 
the needs of the research question. Secondly, since there were 
no patients with mild airflow limitation (GOLD grade 1) in 
the study, our findings may not be extensively applicable to 
this population. Thirdly, the number of women included was 
small, such that our observations may not be generalized to 
all individuals with COPD. This sex bias is due to the lower 
prevalence of COPD in women than in men in our country 
and the underdiagnoses of COPD in women.38,39 Finally, we 
do not exclude that previous oxygen therapy or vasodilator 
treatment in these patients could influence the hemodynamic 
measurements.
Conclusion
In summary, the present study that analyzed a representative 
cohort of COPD patients with varying degrees of airflow 
limitation severity by means of right-heart catheterization 
shows that PH at rest is uncommon in patients with moder-
ate airflow limitation but has a similar prevalence to patients 
with severe and very-severe airflow obstruction from other 
studies, highlighting that airflow limitation is a poor predic-
tor of PH occurrence. In advanced COPD, the coexistence 
of pulmonary gas exchange impairment is of great influence 
on the development of PH. In contrast, an abnormal vascular 
response to exercise was observed in the majority of patients, 
even in those with mild airflow limitation, highlighting the 
notion that pulmonary vascular derangement is an early event 
in the natural history of COPD. Progression of these abnor-
malities may lead to the development of PH that restrains 
the increase of CO during exercise, which might contribute 
to limiting exercise tolerance.
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PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen.
de Neumología y Cirugía Torácica and Instituto de Salud 
Carlos III (EC07/90049).
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Barberà JA, Peinado VI, Santos S. Pulmonary hypertension in 
chronic obstructive pulmonary disease. Eur Respir J. 2003;21(5): 
892–905.
 2. Hoeper MM, Barberà JA, Channick RN, et al. Diagnosis, assessment, 
and treatment of non-pulmonary arterial hypertension pulmonary 
hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S85–S96.
 3. Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic 
lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109–D116.
 4. Oswald-Mammosser M, Apprill M, Bachez P, Ehrhart M, Weitzenblum E. 
Pulmonary hemodynamics in chronic obstructive pulmonary disease of 
the emphysematous type. Respiration. 1991;58(5–6):304–310.
 5. Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, 
Christie JD. Impact of pulmonary artery pressure on exercise function 
in severe COPD. Chest. 2009;136(2):412–419.
 6. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in 
advanced COPD candidates for lung volume reduction surgery or lung 
transplantation. Chest. 2005;127(5):1531–1536.
 7. Scharf SM, Iqbal M, Keller C, et al. Hemodynamic characterization of 
patients with severe emphysema. Am J Respir Crit Care Med. 2002; 
166(3):314–322.
 8. Doi M, Nakano K, Hiramoto T, Kohno N. Significance of pulmonary 
artery pressure in emphysema patients with mild-to-moderate hypox-
emia. Respir Med. 2003;97(8):915–920.
 9. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hyperten-
sion and chronic obstructive pulmonary disease. Am J Respir Crit Care 
Med. 2005;172(2):189–194.
 10. Cuttica MJ, Kalhan R, Shlobin OA, et al. Categorization and impact 
of pulmonary hypertension in patients with advanced COPD. Respir 
Med. 2010;104(12):1877–1882.
 11. Andersen KH, Iversen M, Kjaergaard J, et al. Prevalence, predictors, 
and survival in pulmonary hypertension related to end-stage chronic 
obstructive pulmonary disease. J Heart Lung Transplant. 2012; 31(4): 
373–380.
 12. Kessler R, Faller M, Weitzenblum E, et al. “Natural history” of pulmo-
nary hypertension in a series of 131 patients with chronic obstructive 
lung disease. Am J Respir Crit Care Med. 2001;164(2):219–224.
 13. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, 
management, and prevention of chronic obstructive pulmonary dis-
ease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 
176(6):532–555.
 14. Hilde JM, Skjørten I, Hansteen V, et al. Haemodynamic responses to exer-
cise in patients with COPD. Eur Respir J. 2013;41(5):1031–1041.
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1320
Portillo et al
 15. Boerrigter BG, Bogaard HJ, Trip P, et al. Ventilatory and cardiocircula-
tory exercise profiles in COPD: the role of pulmonary hypertension. 
Chest. 2012;142(5):1166–1174.
 16. Pynnaert C, Lamotte M, Naeije R. Aerobic exercise capacity in COPD 
patients with and without pulmonary hypertension. Respir Med. 2010; 
104(1):121–126.
 17. Barberà JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez- 
Roisin R. Worsening of pulmonary gas exchange with nitric oxide 
inhalation in chronic obstructive pulmonary disease. Lancet. 1996; 
347(8999):436–440.
 18. Roger N, Barberà JA, Roca J, Rovira I, Gómez FP, Rodriguez-Roisin R. 
Nitric oxide inhalation during exercise in chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med. 1997;156(3 Pt 1):800–806.
 19. Agustí AG, Barberá JA, Roca J, Wagner PD, Guitart R, Rodriguez-
Roisín R. Hypoxic pulmonary vasoconstriction and gas exchange during 
exercise in chronic obstructive pulmonary disease. Chest. 1990;97(2): 
268–275.
 20. Ribas J, Díaz O, Barberà JA, et al. Invasive exercise testing in the evalu-
ation of patients at high-risk for lung resection. Eur Respir J. 1998; 
12(6):1429–1435.
 21. Ribas J, Jiménez MJ, Barberà JA, et al. Gas exchange and pulmonary 
hemodynamics during lung resection in patients at increased risk: 
relationship with preoperative exercise testing. Chest. 2001;120(3): 
852–859.
 22. Peinado VI, Gómez FP, Barberà JA, et al. Pulmonary vascular abnor-
malities in chronic obstructive pulmonary disease undergoing lung 
transplant. J Heart Lung Transplant. 2013;32(12):1262–1269.
 23. Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange 
effects of sildenafil in patients with chronic obstructive pulmonary dis-
ease and pulmonary hypertension. Am J Respir Crit Care Med. 2010; 
181(3):270–278.
 24. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, 
management, and prevention of chronic obstructive pulmonary dis-
ease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 
187(4):347–365.
 25. Saggar R, Lewis GD, Systrom DM, Champion HC, Naeije R, Saggar R. 
Pulmonary vascular response to exercise: a haemodynamic observation. 
Eur Respir J. 2012;39(2):231–234.
 26. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial 
pressure during rest and exercise in healthy subjects: a systematic 
review. Eur Respir J. 2009;34(4):888–894.
 27. Miller MR, Crapo R, Hankinson J, et al. General considerations for 
lung function testing. Eur Respir J. 2005;26(1):153–161.
 28. Roca J, Sanchis J, Agusti-Vidal A, et al. Spirometric reference val-
ues for a Mediterranean population. Bull Eur Physiopathol Respir. 
1986;22(3):217–224.
 29. Roca J, Rodriguez-Roisin R, Cobo E, Burgos F, Perez J, Clausen JL. 
Single-breath carbon monoxide diffusing capacity prediction equations 
from a Mediterranean population. Am Rev Respir Dis. 1990;141(4 Pt 1): 
1026–1032.
 30. Nelson LD, Rutherford EJ. Principles of hemodynamic monitoring. 
In: Pinsky MR, Dhainaut JF, editors. Pathophysiologic Foundations 
of Critical Care. Baltimore, MD: Williams and Wilkins; 1993:3–22.
 31. Barberà JA. The pulmonary vasculature of COPD. In: Rennard SI, 
Rodríguez-Roisin R, Huchon G, Roche N, editors. Clinical manage-
ment of chronic obstructive lung disease. 2nd ed. New York: Informa 
Healthcare; 2008:189–205.
 32. Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in 
COPD: results from the ASPIRE registry. Eur Respir J. 2013;41(6): 
1292–1301.
 33. Lau EM, Manes A, Celermajer DS, Galiè N. Early detection of pulmo-
nary vascular disease in pulmonary arterial hypertension: time to move 
forward. Eur Heart J. 2011;32(20):2489–2898.
 34. Christensen CC, Ryg MS, Edvardsen A, Skjønsberg OH. Relationship 
between exercise desaturation and pulmonary haemodynamics in COPD 
patients. Eur Respir J. 2004;24(4):580–586.
 35. Kovacs G, Olschewski A, Berghold A, Olschewski H. Pulmonary vascu-
lar resistances during exercise in normal subjects: a systematic review. 
Eur Respir J. 2012;39(2):319–328.
 36. Peinado VI, Pizarro S, Barberà JA. Pulmonary vascular involvement 
in COPD. Chest. 2008;134(4):808–814.
 37. Skjørten I, Hilde JM, Melsom MN, Hansteen V, Steine K, Humerfelt S. 
Pulmonary artery pressure and PaO
2
 in chronic obstructive pulmonary 
disease. Respir Med. 2013;107(8):1271–1279.
 38. Miravitlles M, Soriano JB, Garcia-Rio R, et al. Prevalence of COPD 
in Spain: impact of undiagnosed COPD on quality of life and daily life 
activities. Thorax. 2009;64(10):863–868.
 39. Ancochea J, Miravitlles M, García-Río F, et al. Underdiagnoses of 
chronic obstructive pulmonary disease in women: quantification of the 
problem, determinants and proposals for action. Arch Bronconeumol. 
2013;49(6):223–229. English, Spanish.
